SEPHguarding acute myeloid leukemia.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35245465.
- Also identified by DOI 10.1016/j.stem.2022.02.007.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Adaptive aberrant gene regulation is a hallmark of malignant growth and therapy resistance in acute myeloid leukemia (AML). In this issue of Cell Stem Cell, Eagle et al. identified oncogenic enhancer-driven overexpression of selenophosphate synthetase 2 (SEPHS2) as an opportunity for targeted mitigation of malignant cell growth in AML.
Medical subject headings
- Leukemia, Myeloid, Acute